Influenza A virus H7N9 vaccine - EpiVax

Drug Profile

Influenza A virus H7N9 vaccine - EpiVax

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator EpiVax
  • Class Influenza A vaccines; Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Influenza A virus H7N9 subtype

Most Recent Events

  • 12 Sep 2016 Early research in Influenza-A virus H7N9 subtype (Prevention) in USA (IM)
  • 12 Sep 2016 EpiVax plans a phase I trial for Influenza-A virus H7N9 subtype (Prevention) in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top